Association between syndecan-4 and subclinical atherosclerosis in ankylosing spondylitis
Background: Despite advances in the diagnosis and treatment of ankylosing spondylitis (AS), the risk of cardiovascular complications in AS patients is still higher than in the general population. Macrophages are at the intersection of the basic pathogenetic processes of AS and atherosclerosis. Altho...
Saved in:
Published in | Medicine (Baltimore) Vol. 103; no. 3; p. e37019 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
19.01.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background:
Despite advances in the diagnosis and treatment of ankylosing spondylitis (AS), the risk of cardiovascular complications in AS patients is still higher than in the general population. Macrophages are at the intersection of the basic pathogenetic processes of AS and atherosclerosis. Although syndecan-4 (SDC4) mediates a variety of biological processes, the role of SDC4 in macrophage-mediated atherogenesis in AS patients remains unclear. Herein, we aimed to investigate the role of SDC4 in subclinical atherosclerosis in AS patients.
Methods:
Subjects were selected from eligible AS patients and control subjects without a prior history of AS who were referred to the rheumatology outpatient clinics. All participants' past medical records and clinical, and demographic characteristics were scanned. In addition, carotid intima-media thickness (CIMT) measurement and disease activity index measurement were applied to all patients.
Results:
According to our data, serum SDC4 level was significantly higher among AS patients compared with the control group (6.7 [1.5-35.0] ng/mL vs 5.1 [0.1-12.5] ng/mL, P < .001). The calculated CIMT was also significantly higher in AS patients than in the control group (0.6 [0.3-0.9] mm vs 0.4 (0.2-0.7), P < .001]. Additionally, serum C-reactive protein level and SDC4 level were independent predictors of AS and strongly associated with CIMT. Linear regression analysis showed that serum SDC4 level was the best predictor of CIMT (P = .004).
Conclusion:
Our data indicate that serum SDC4 levels provide comprehensive information about the clinical activity of the disease and subclinical atherosclerosis in AS patients. |
---|---|
Bibliography: | Received: 11 August 2023 / Received in final form: 29 November 2023 / Accepted: 2 January 2024 The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request. The authors have no funding and conflicts of interest to disclose. How to cite this article: Sertdemir AL, Şahin AT, Duran M, Çelik M, Tatar S, Oktay İ, Alsancak Y. Association between syndecan-4 and subclinical atherosclerosis in ankylosing spondylitis. Medicine 2024;103:3(e37019). * Correspondence: Ahmet T. Sahin, Department of Cardiology, Faculty of Medicine, Necmettin Erbakan University, Eski Meram Street 19 CA/1, Meram/Konya 42090, Turkiye. (e-mail: tahasahin94@gmail.com). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0025-7974 1536-5964 1536-5964 |
DOI: | 10.1097/MD.0000000000037019 |